Cardiovascular effectiveness was observed, largely independent of age, in a cohort of older patients with type 2 diabetes.

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established atherosclerotic disease, CKD, or both.

GLP-1 receptor agonists were associated with improved survival and reduced graft loss among kidney transplant recipients with type 2 diabetes.

SGLT2 inhibitors such as empagliflozin, and GLP-1 agonists such as semaglutide (in people with both HFpEF and obesity). These drugs help people lose weight and have also been shown to reduce ...

SGLT2 inhibitors such as empagliflozin, and GLP-1 agonists such as semaglutide (in people with both HFpEF and obesity). These drugs help people lose weight and have also been shown to reduce ...

While furosemide and other diuretics can help with symptoms, the drugs that have had a very significant impact on the management of HFpEF have been drugs that were initially used for diabetes, SGLT2 ...